Delisting riskPopularity #4,282
QNCX · NASDAQ · Biotechnology

Quince Therapeutics (QNCX)

Develops inhaled sirolimus for pulmonary hypertension and bronchiolitis obliterans syndrome.

$29.49
vs last close−1.86 (−5.94%)